Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Margherita Tafuro
Observed name:
M. Tafuro
Institutions:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Scuola Superiore Meridionale
Observed institutions:
Federico II University Hospital,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Scuola Superiore Meridionale,
University of Naples Federico II
ORCID:
0009-0009-8883-1426
Observed ORCID:
0009-0009-8883-1426
OpenAlex ID:
A5010994601
CAR-T cell therapy for breast cancer: Current status and future perspective
2024
·
Giuseppe Buono
, Monica Capozzi
, et al.
·
Cancer Treatment Reviews
·
31
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives
2025
·
Vincenzo Di Lauro
, Alessandro Rizzo
, et al.
·
Cancer Treatment Reviews
·
16
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study
2022
·
Pietro De Placido
, Erica Pietroluongo
, et al.
·
Frontiers in Oncology
·
10
PDF
Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis
2024
·
Roberto Buonaiuto
, Aldo Caltavituro
, et al.
·
The Breast
·
6
PDF
Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study
2025
·
Pietro De Placido
, Rossana Di Rienzo
, et al.
·
European Journal of Cancer
·
4
Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials
2026
·
Roberto Buonaiuto
, Federica Pia Mangiacotti
, et al.
·
The Breast
·
2
The long road after breast cancer: survivorship issues and long-term treatment effects in young women
2026
·
Martina Pagliuca
, Roberto Buonaiuto
, et al.
·
Frontiers in Oncology
·
1
PDF
CDK4/6i in the Underrepresented Histological Subtypes of HR±/HER2- Metastatic Breast Cancer: A Real-World Cohort Study of Effectiveness and Safety
2026
·
Claudia von Arx
, Alessandra Calabrese
, et al.
·
Clinical Breast Cancer
568eP Early progression to CDK4/6 inhibitors plus endocrine therapy in HR+/HER2− metastatic breast cancer: A real-world analysis
2026
·
M. Tafuro
, M. Piezzo
, et al.
·
ESMO Open
457P Real-world outcomes and immunotherapy efficacy in patients with ER-low and triple-negative metastatic breast cancer: A GIM14 multicenter retrospective analysis
2026
·
T. Ruelle
, E. Blondeaux
, et al.
·
ESMO Open
PDF
557eP OVAL-T-Dxd: Real-world assessment of ovarian function suppression (OFS) during trastuzumab deruxtecan (T-Dxd) therapy in premenopausal, hormone-receptor–positive (HR+/HER2-Low) metastatic breast cancer (mBC)
2026
·
S. Parola
, O. Tinelli
, et al.
·
ESMO Open
PDF
AB003. Unexpected long-lasting control of thymic carcinoma treated with anti-PD1 and oral etoposide: a real-life experience of combination therapy
2023
·
Margaret Ottaviano
, Sara Parola
, et al.
·
Mediastinum
AB013. Occurrence and severity of COVID-19 in patients affected by thymic epithelial tumors with or without Good’s syndrome: a single centre experience
2023
·
Erica Pietroluongo
, Pietro De Placido
, et al.
·
Mediastinum
Effect of SARS-CoV-2 mRNA vaccine booster in serologically negative patients with thymic epithelial tumors.
2023
·
Erica Pietroluongo
, Pietro De Placido
, et al.
·
Journal of Clinical Oncology
Immunological signature of patients with thymic epithelial tumors and Good syndrome: Correlation with clinical outcome.
2023
·
Rocco Morra
, Erica Pietroluongo
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
15
Citation count:
70
H-index:
4
I10-index:
3
Year
Topic
Type